Similarly, erlotinib and gefitinib are both preferential inhibitors of EGFR, and share analogous chemical structure19, 20; but post‐absorption, gefitinib is localized to a greater extent in tumour tissue, whereas erlotinib preferentially accumulates in plasma.21 The gene discussed is EGFR; the disease is neoplasm.